Albiglutide shows efficacy in A1C control, fewer side effects

Research published in The Lancet Diabetes & Endocrinology showed type 2 diabetes patients who took once-weekly albiglutide attained significant reductions in A1C, comparable with those who were on once-daily liraglutide. "The data indicate that albiglutide is a reasonable alternative to other glu...

Share

This news summary appeared in DiabetesPro SmartBrief on 03/12/2014
Click here to view the full issue.


View the original article:
Medscape (free registration)

Want to see more news summaries?
Sign up for DiabetesPro SmartBrief

DiabetesPro SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities